Literature DB >> 30936155

Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.

Sakineh Pirahmadi1, Sedigheh Zakeri2, Akram A Mehrizi1, Navid D Djadid1, Abbas-Ali Raz1, Jafar J Sani1.   

Abstract

Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS) is an advanced vaccine candidate that has a crucial role in the traversal of the malaria parasite in both mosquito and mammalian hosts. As recombinant purified proteins are normally poor immunogens, they require to be admixed with an adjuvant(s); therefore, the objective of the present study was to evaluate the capacity of different vaccine adjuvants, monophosphoryl lipid A (MPL), CpG, and Quillaja saponaria Molina fraction 21 (QS-21), alone or in combination (MCQ [MPL/CpG/QS-21]), to enhance the immunogenicity of Escherichia coli-expressed PfCelTOS in BALB/c mice. This goal was achieved by the assessment of anti-PfCelTOS IgG antibodies (level, titer, IgG isotype profile, avidity, and persistence) and extracellular Th1 cytokines using an enzyme-linked immunosorbent assay (ELISA) on postimmunized BALB/c mouse sera and PfCelTOS-stimulated splenocytes, respectively. Also, an assessment of the transmission-reducing activity (TRA) of anti-PfCelTOS obtained from different vaccine groups was carried out in female Anopheles stephensi mosquitoes by using a standard membrane feeding assay (SMFA). In comparison to PfCelTOS alone, administration of PfCelTOS with three distinct potent Th1 adjuvants in vaccine mouse groups showed enhancement and improvement of PfCelTOS immunogenicity that generated more bias toward a Th1 response with significantly enhanced titers and avidity of the anti-PfCelTOS responses that could impair ookinete development in A. stephensi However, immunization of mice with PfCelTOS with MCQ mixture adjuvants resulted in the highest levels of induction of antibody titers, avidity, and inhibitory antibodies in oocyst development (88%/26.7% reductions in intensity/prevalence) in A. stephensi It could be suggested that adjuvant combinations with different mechanisms stimulate better functional antibody responses than adjuvants individually against challenging diseases such as malaria.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  CpG; MPL; PfCelTOS; Plasmodium falciparumzzm321990; QS-21; adjuvants; malaria; vaccine

Mesh:

Substances:

Year:  2019        PMID: 30936155      PMCID: PMC6529666          DOI: 10.1128/IAI.00911-18

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  77 in total

1.  The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.

Authors:  A Moore; L McCarthy; K H Mills
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

2.  Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.

Authors:  Scott A Halperin; Simon Dobson; Shelly McNeil; Joanne M Langley; Bruce Smith; Robyn McCall-Sani; Dan Levitt; Gary Van Nest; Daniel Gennevois; Joseph J Eiden
Journal:  Vaccine       Date:  2005-09-12       Impact factor: 3.641

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.

Authors:  Toshiyuki Sugai; Masaaki Mori; Masatoshi Nakazawa; Motohide Ichino; Takuya Naruto; Naoki Kobayashi; Yoshinori Kobayashi; Mutsuhiko Minami; Shumpei Yokota
Journal:  Vaccine       Date:  2005-06-21       Impact factor: 3.641

5.  Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Authors:  Christopher B Fox; Susan L Baldwin; Thomas S Vedvick; Evelina Angov; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2012-08-15

6.  Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).

Authors:  M Hopkins; B G Lees; D G Richardson; S R Woroniecki; A W Wheeler
Journal:  Allergol Immunopathol (Madr)       Date:  2001 Nov-Dec       Impact factor: 1.667

Review 7.  A research agenda for malaria eradication: vaccines.

Authors: 
Journal:  PLoS Med       Date:  2011-01-25       Impact factor: 11.069

Review 8.  From discovery to licensure, the Adjuvant System story.

Authors:  Nathalie Garçon; Alberta Di Pasquale
Journal:  Hum Vaccin Immunother       Date:  2016-09-16       Impact factor: 3.452

9.  The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.

Authors:  Diego A Espinosa; Joel Vega-Rodriguez; Yevel Flores-Garcia; Amy R Noe; Christian Muñoz; Russell Coleman; Torben Bruck; Keith Haney; Alex Stevens; Diane Retallack; Jeff Allen; Thomas S Vedvick; Christopher B Fox; Steven G Reed; Randall F Howard; Ahmed M Salman; Chris J Janse; Shahid M Khan; Fidel Zavala; Gabriel M Gutierrez
Journal:  Infect Immun       Date:  2017-01-26       Impact factor: 3.441

10.  QS-21: A Potent Vaccine Adjuvant.

Authors:  Daming Zhu; Wenbin Tuo
Journal:  Nat Prod Chem Res       Date:  2015-07-31
View more
  2 in total

Review 1.  Advances in Oral Subunit Vaccine Design.

Authors:  Hans Van der Weken; Eric Cox; Bert Devriendt
Journal:  Vaccines (Basel)       Date:  2020-12-22

Review 2.  Adjuvants: friends in vaccine formulations against infectious diseases.

Authors:  G G Guerrero Manriquez; I Tuero
Journal:  Hum Vaccin Immunother       Date:  2021-07-21       Impact factor: 4.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.